Colorectal Cancer (CRC) Active Not Recruiting Phase 2 Trials for Oxaliplatin (DB00526)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Active Not Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT07801352	CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer	Treatment	Artenimol (DB11638) Capecitabine (DB01101) Oxaliplatin (DB00526) Tislelizumab (DB14922)
NCT06268015	Botensilimab and Balstilimab Optimization in Colorectal Cancer	Treatment	Balstilimab (DB15676) Bevacizumab (DB00112) Botensilimab (DB16651) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526) Panitumumab (DB01269)
NCT04715633	PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer	Treatment	Camrelizumab (DB14776) Capecitabine (DB01101) Oxaliplatin (DB00526) Rivoceranib (DB14765)
NCT03493048	Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM	Treatment	Cetuximab (DB00002) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT02758951	Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases	Treatment	Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT00335816	Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer	Treatment	Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT00492999	Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver	Treatment	Dexamethasone (DB01234) Floxuridine (DB00322) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT06106308	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Onvansertib (DB15110) Oxaliplatin (DB00526)
NCT05945901	A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) HR070803 (DB26995) Leucovorin (DB00650) Oxaliplatin (DB00526)